Cracking the Code of Rare Brain Diseases -A Clinical Insight on Progressive Multifocal Leukoencephlopathy
Main Article Content
Abstract
Rare diseases of the central nervous system (CNS) represent an enormous, yet frequently overlooked, health burden; this is particularly true in countries like India, where the agenda is predominantly dominated by infectious and lifestyle diseases. This largely stems from the fact that rare diseases are usually of genetic origin or neurodegenerative in nature where patients encounter diagnostic delays and treatment options are limited because of accessibility to specialized care. Progressive Multifocal Leukoencephalopathy (PML) is a rare demyelinating disorder which has been diagnosed more often in recent times and continues to be a health burden for many. *¹
Progressive Multifocal Leukoencephalopathy (PML) represents a rare yet increasingly diagnosed condition which results from the JC virus reactivation in people with weakened immune systems. The immune system suppression caused by natalizumab and rituximab and fingolimod has led to the emergence of PML cases among patients despite its previous history of occurrence mainly in AIDS patients. In PML, JC virus reactivation leads to infection of oligodendrocytes, culminating in widespread demyelination which produces symptoms that include motor and visual impairments along with cognitive deterioration and ataxia. *²
Medical professionals diagnose the condition by analyzing MRI results along with JC virus DNA presence in cerebrospinal fluid. The main obstacle to early detection exists because PML symptoms resemble other CNS diseases. Currently, immune reconstitution remains the cornerstone of PML management by antiretroviral therapy for HIV patients and immunosuppressant withdrawal for others. This article establishes the urgent necessity to raise awareness about rare CNS diseases while promoting genetic testing alongside patient learning and healthcare policies that support these conditions. The research demonstrates how studying uncommon medical disorders contributes to expanding knowledge about neurological and immunological systems. *³
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
• Abstract
• Du Pasquier RA, & Koralnik IJ. (2013). JC virus infection in the central nervous system. Clinical and Developmental Immunology, 2013:373579.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. The Lancet Neurology, 9(4), 425–437.
• White MK, & Khalili K. (2011). Pathogenesis of progressive multifocal leukoencephalopathy: a molecular update. FEBS Journal, 278(22), 4116–4126.
Introduction
• Du Pasquier RA, & Koralnik IJ. (2013). JC virus infection in the central nervous system. Clinical and Developmental Immunology, 2013:373579.
• Koralnik IJ. (2006). Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Annals of Neurology, 60(2), 162–173.
• White MK, & Khalili K. (2011). Pathogenesis of progressive multifocal leukoencephalopathy: a molecular update. FEBS Journal, 278(22), 4116–4126.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.
Etiology and Pathogenesis
• Du Pasquier RA, & Koralnik IJ. (2013). JC virus infection in the central nervous system. Clinical and Developmental Immunology, 2013:373579.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.
• Hoang-Xuan K, Delattre JY, Assan R, et al. (1986). Progressive multifocal leukoencephalopathy in AIDS: clinical and neuropathological features. Journal of Neurology, Neurosurgery & Psychiatry, 49(11), 1324–1330.
• Major EO, Amemiya K, Tornatore CS, et al. (1992). Biology of JC virus and progressive multifocal leukoencephalopathy. Annals of Neurology, 31(5), 503–511.
• Wüthrich C, Montrasio F, Sawa M, et al. (2012). Progressive multifocal leukoencephalopathy in patients with immune-mediated diseases. Neurology, 79(14), 1445–1451.
• Tan CS, Ellis LC, Sejvar JJ, et al. (2013). The effect of natalizumab on JC virus serology and incidence of PML in multiple sclerosis patients. Neurology, 81(6), 512–518.
• Bloomgren G, Richman S, Hotermans C, et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine, 366(20), 1870–1880.
• Clifford DB, Ances BM, Costello C, et al. (2011). Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Archives of Neurology, 68(9), 1156–1164.
• Richardson EP Jr, & Berger JR. (1998). Progressive multifocal leukoencephalopathy and human immunodeficiency virus infection. Journal of NeuroVirology, 4(1), 45–57.
• D’Arcy S, Galvin A, Coffey E, et al. (2015). JC virus infection in congenital immunodeficiency: a rare cause of PML. Journal of Clinical Virology, 68, 62–64.
Epidemiology
• Koralnik IJ, & Tyler KL. (2016). Progressive multifocal leukoencephalopathy: current insights. Nature Reviews Neurology, 12(4), 211–222.
• Berger JR, & Houff S. (2006). Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurologic Clinics, 24(3), 547–567.
• Ho D, & Tourbah A. (2014). Progress in diagnosis and management of PML in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 85(10), 1157–1163.
Clinical Presentation
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.
• Koralnik IJ, & Wüthrich C. (2007). Visual manifestations of JC virus infection in the CNS. Neurology, 68(1), 36–38.
• Marzocchetti A, Tompkins T, Clifford DB, et al. (2009). Cognitive impairment and survival in PML patients. Neurology, 72(5), 431–436.
• Cinque P, Koralnik IJ, & Clifford DB. (2003). Progressive multifocal leukoencephalopathy in HIV infection: pathogenesis and treatment. The Lancet Infectious Diseases, 3(12), 795–803.
• Cortese I, Reich DS, & Nath A. (2021). Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nature Reviews Neurology, 17(1), 37–51.
• Berger JR, Aksamit AJ, Clifford DB, et al. (2013). PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology, 80(15), 1430–1438.
Diagnosis
• Berger JR, Aksamit AJ, Clifford DB, et al. (2013). PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology, 80(15), 1430–1438.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.
Treatment and Management
• Tan CS, & Koralnik IJ. (2018). Novel immunotherapies and PML: balance between efficacy and safety. Neurology, 90(4), 163–170.
• Cortese I, Reich DS, & Nath A. (2021). Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nature Reviews Neurology, 17(1), 37–51.
Prevention and Monitoring
• Bloomgren G, Richman S, Hotermans C, et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine, 366(20), 1870–1880.
• Ho D, & Tourbah A. (2014). Progress in diagnosis and management of PML in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 85(10), 1157–1163.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.
Prognosis
• Berger JR, Aksamit AJ, Clifford DB, et al. (2013). PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology, 80(15), 1430–1438.
• Tan CS, & Koralnik IJ. (2018). Progressive multifocal leukoencephalopathy: current treatment options and future directions. Therapeutic Advances in Neurological Disorders, 11, 1–15.
Future Directions
• Tan CS, & Koralnik IJ. (2018). Progressive multifocal leukoencephalopathy: current treatment options and future directions. Therapeutic Advances in Neurological Disorders, 11, 1–15.
• Cortese I, Reich DS, & Nath A. (2021). Progressive multifocal leukoencephalopathy and the spectrum of JC virus–related disease. Nature Reviews Neurology, 17(1), 37–51.
Breaking Down PML (Q&A)
• Du Pasquier RA, & Koralnik IJ. (2013). JC virus infection in the central nervous system. Clinical and Developmental Immunology, 2013:373579.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.
• Berger JR, Aksamit AJ, Clifford DB, et al. (2013). PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology, 80(15), 1430–1438.
• Bloomgren G, Richman S, Hotermans C, et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine, 366(20), 1870–1880.
Myths vs Facts
• Koralnik IJ, & Tyler KL. (2016). Progressive multifocal leukoencephalopathy: current insights. Nature Reviews Neurology, 12(4), 211–222.
• Du Pasquier RA, & Koralnik IJ. (2013). JC virus infection in the central nervous system. Clinical and Developmental Immunology, 2013:373579.
• Cortese I, Reich DS, & Nath A. (2021). Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nature Reviews Neurology, 17(1), 37–51.
• Tan CS, & Koralnik IJ. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus. The Lancet Neurology, 9(4), 425–437.